MedPath

ASAN FOUNDATION

ASAN FOUNDATION logo
🇰🇷South Korea
Ownership
Private
Established
1989-06-23
Employees
501
Market Cap
-
Website
https://ails.amc.seoul.kr

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
Leukemia
Myelodysplastic/Myeloproliferative Neoplasms
First Posted Date
2008-03-03
Last Posted Date
2013-03-26
Lead Sponsor
Asan Medical Center
Target Recruit Count
52
Registration Number
NCT00627666
Locations
🇰🇷

Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2008-02-20
Last Posted Date
2013-03-26
Lead Sponsor
Asan Medical Center
Target Recruit Count
50
Registration Number
NCT00618501
Locations
🇰🇷

Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

Phase 2
Completed
Conditions
Metastatic Renal Cell Carcinoma
Interventions
First Posted Date
2007-12-11
Last Posted Date
2014-09-25
Lead Sponsor
Asan Medical Center
Target Recruit Count
76
Registration Number
NCT00570882
Locations
🇰🇷

Yeungnam University Medical Center, Daegu, Korea, Republic of

🇰🇷

Daegu Catholic University Hospital, Daegu, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Phase 1
Completed
Conditions
Cancer
First Posted Date
2007-12-07
Last Posted Date
2013-03-26
Lead Sponsor
Asan Medical Center
Target Recruit Count
18
Registration Number
NCT00569283
Locations
🇰🇷

Korea Research Institute of Bioscience and Biotechnology, Dajeon, Korea, Republic of

🇰🇷

Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

Phase 1
Completed
Conditions
Advanced Gastric Cancer
Interventions
Drug: Capecitabine, Cisplatin, Sorafenib
First Posted Date
2007-11-29
Last Posted Date
2020-01-18
Lead Sponsor
Asan Medical Center
Target Recruit Count
22
Registration Number
NCT00565370
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Not Applicable
Completed
Conditions
Nonmalignant Neoplasm
Multiple Myeloma and Plasma Cell Neoplasm
Lymphoma
Leukemia
Unspecified Adult Solid Tumor, Protocol Specific
Myelodysplastic Syndromes
First Posted Date
2007-08-27
Last Posted Date
2013-03-26
Lead Sponsor
Asan Medical Center
Target Recruit Count
30
Registration Number
NCT00521430
Locations
🇰🇷

Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
Procedure: PET/CT
First Posted Date
2007-05-01
Last Posted Date
2016-01-13
Lead Sponsor
Asan Medical Center
Target Recruit Count
78
Registration Number
NCT00468078
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction

Phase 3
Completed
Conditions
Bile Duct Obstruction
Interventions
Device: Paclitaxel eluting covered metal stent and control covered metal stent
First Posted Date
2007-03-28
Last Posted Date
2010-06-11
Lead Sponsor
Asan Medical Center
Target Recruit Count
52
Registration Number
NCT00453076
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Overcome Biochemical Aspirin Resistance Through Cilostazol Combination

Phase 4
Completed
Conditions
Cerebral Infarction
Interventions
Drug: placebo
First Posted Date
2007-03-13
Last Posted Date
2010-01-18
Lead Sponsor
Asan Medical Center
Target Recruit Count
244
Registration Number
NCT00446641
Locations
🇰🇷

Jae-Kwan Cha, Busan, Korea, Republic of

🇰🇷

Kangdong Sacred Heart Hospital, Hallym University, Seoul, Korea, Republic of

🇰🇷

Eulji University Hospital, Daejon, Korea, Republic of

and more 1 locations

Study of Pyridoxine for Hand-Foot Syndrome

Phase 3
Completed
Conditions
Hand-foot Syndrome
Interventions
Drug: Placebo
First Posted Date
2007-03-12
Last Posted Date
2014-02-25
Lead Sponsor
Asan Medical Center
Target Recruit Count
389
Registration Number
NCT00446147
© Copyright 2025. All Rights Reserved by MedPath